A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506
This study is recruiting at 11 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PIK3CA Mutations
- Advanced Solid Tumors, Adult
- Endometrial Cancer
- HR Positive/HER-2 Negative Breast Cancer
- HER2-low Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Cogent Biosciences, Inc.
- Last updated on ClinicalTrials.gov
- August 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- HonorHealth Research Institute · Scottsdale, AZ
California · 1
- START Los Angeles · Los Angeles, CA
Colorado · 1
- Sarah Cannon Research Institute (SCRI) at HealthONE-Denver · Denver, CO
Florida · 1
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. · Tampa, FL
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Missouri · 1
- Washington University School of Medicine - Siteman Cancer Center · St Louis, MO
New Jersey · 1
- START New Jersey, LLC · East Brunswick, NJ
Tennessee · 1
- SCRI Oncology Partners - Nashville · Nashville, TN
Texas · 1
- NEXT Austin · Austin, TX
Utah · 1
- START Mountain Region, LLC · West Valley City, UT
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.